Navigation Links
Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss
Date:5/26/2011

rcaserin NDA, including related plans and activities; the Eisai collaboration and potential activities thereunder; lorcaserin's patent coverage; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs, including for lorcaserin, may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
6. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
7. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
8. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
9. EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014  ResMed (NYSE: RMD ) ... Exchange program, a comprehensive suite of software and ... other health care providers. ResMed ... patient information. It integrates valuable sleep and respiratory ... management platforms with customers, in-house or third-party electronic ...
(Date:10/20/2014)... , Oct. 20, 2014   Taiho Oncology, ... Ltd. ( Japan ), announced that ... Fast Track designation for TAS-102 (nonproprietary names: trifluridine ... under investigation for the treatment of refractory metastatic ... initiated a rolling NDA submission to the FDA. ...
(Date:10/20/2014)... LONDON , October 20, 2014 ... study of its novel, low volume bowel preparation, NER1006, ... of the American College of Gastroenterology (ACG), ... end point of stool weight and co-primary endpoint of ... efficacy with NER1006 vs. MOVIPREP ® in screening ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... 7 MO BIO Laboratories, Inc., the ... announces the launch of a groundbreaking new product, LifeGuard ... samples upon collection. LifeGuard solution will enable researchers ... degradation or changes in transcript levels during transport to ...
... RIDGE, N.J., Oct. 7 With the growth in the ... WIRELESS I.T. & Entertainment 2009® that it is offering OnCare ... Manager application that helps address the specific needs of mobile ... efficient. , Designed specifically for use by home ...
Cached Medicine Technology:MO BIO Laboratories, Inc. Launches LifeGuard(TM) Soil Preservation Solution 2Verizon Wireless Offers Home Health Care Industry Custom Mobile Application To Be More Productive 2
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
(Date:10/20/2014)... October 20, 2014 My Clients Plus ... software application. The new module enables easy administration ... full life-cycle quality care. , This application allows users ... their practice, attach a to-do item to a specific ... even set up reoccurring reminders for follow-ups. It's ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... October 20, 2014 It’s hard to imagine ... orphans and vulnerable children around the world, it’s a reality. ... people, many children are forced to walk barefoot on rocky ... families or play with their friends. , Buckner International's ... Air1 Radio in October to encourage support for ...
(Date:10/19/2014)... October 20, 2014 The leading ... ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best ... platforms for those who want to buy high ... time. , The IT manager of Top10BestSEOHosting.com says, ... most recommended suppliers for everyone. A lot of ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2
... District Health Boards (DHBs), striking junior doctors returned to hospital calling ... , ,The doctor's union - Resident Doctors' Association (RDA) and the ... Monday and planned to meet on Thursday for confirming the results. ... strike, which lasted for 5 days. , ,But unfortunately ...
... A new study conducted in Australia by the NSW Centre ... the eating habits of Australian children //. ,In ... show many kids quite frequently miss meals. The researchers interviewed ... what they ate and drank. ,They conducted this ...
... to a Danish study conducted by Dr. Morten Andersen of ... that doctors //who took part in pharmaceutical-sponsored clinical trials tend ... the Journal of the American Medical Association. The research team ... doctor knows the product well. It is also due to ...
... in hospitals against reservation policy there is yet another ... it is by the staff and the venue is ... is the incident wherein some RSS people unleashed violence ... steps to check overcrowding of the wards. ,The ...
... suffering, a tuberculosis (TB) patient in Madhya Pradesh has requested Indian ... life and that of his four minor children. ... late 40s, is suffering from TB and has long been dependent ... of TB a few years ago. ,He has now ...
... University study, members of rural Appalachian households who have minimal ... to become obese and develop diabetes. ,Researcher David ... 'food insecurity' had a greater body mass index (BMI) ... (an average BMI of 30.3 vs. average BMI of 29). ...
Cached Medicine News:Health News:Childhood Obesity Cause For Increasing Concerns 2Health News:Appalachians more prone to obesity and diabetes 2Health News:Appalachians more prone to obesity and diabetes 3
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
... Hematology-16 Control is specifically ... most hematology analyzers that ... parameters and 3-part white ... trilevel control can be ...
Each Liquichek Seroconversion Panel features a series of serum specimens drawn over time from one individual to show the progression from a negative to a positive disease state....
Medicine Products: